APO-Pemetrexed pemetrexed 100 mg (as disodium) powder for injection vial

Active ingredient:

pemetrexed disodium hemipentahydrate, Quantity: 120.8 mg (Equivalent: pemetrexed, Qty 100 mg)

Available from:

Arrotex Pharmaceuticals Pty Ltd

INN (International Name):

pemetrexed disodium hemipentahydrate

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: mannitol; hydrochloric acid; sodium hydroxide

Administration route:

Intravenous Infusion

Units in package:

1

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell Lung Cancer (NSCLC),Pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology.,Pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic NSCLC other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Product summary:

Visual Identification: White to either light yellow or green-yellow powder.; Container Type: Vial; Container Material: Glass; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Licence status A

Authorization date:

2014-09-04